Novel Treatment Path in Oncology
Minimally-invasive, treatment combines photosensitive drug activated by a light delivery system. Utilizing a low-energy, non-thermal laser light channeled through optical fibers, this treatment provides a new approach to localized tumors, with potential for treating various sites in the body.
An Oncology Revolution with Significant Value Potential
Lead indication approved in EU, IS, Mexico. Submission of NDA for accelerated approval accepted by FDA
~$18B market potential as single agent and as immuno-oncology combination
Primed for Growth
Full WW rights/ value retained; >$40mn non-dilutive funding; backed by leading centers
US launch of lead indication and multiple pipeline readouts anticipated for 1H 2020